Diagnostic microbiology and infectious disease · 2026
Molecular mechanisms underlying streptomycin resistance driven by gidB R96C and A133P in M. tuberculosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Tiantian, Li Xinxin, Yao Jiachen, Wang Qirong, Chong Yingzhi, Han Tiesheng, Ren Qi, An Ziyue, Feng Fumin
Аннотация
OBJECTIVE: To characterize the functional roles of gidB mutations R96C and A133P in streptomycin (SM) resistance of Mycobacterium tuberculosis (Mtb), elucidate their molecular mechanisms, and provide experimental basis for clinical molecular diagnosis of SM-resistant tuberculosis.
METHODS: SM-resistant Mtb isolates (n = 75) were collected between June 2020-August 2021 from Shijiazhuang Fifth Hospital. gidB mutations were identified via whole-genome sequencing (WGS). Recombinant Mycobacterium smegmatis strains expressing wild-type, R96C, or A133P Mtb-gidB were constructed. MIC assay, growth curve analysis, qRT-PCR, Western blot, cellular thermal shift assay (CETSA), molecular docking, and molecular dynamics (MD) simulation were used to assess phenotypic changes, gene/protein expression, SM binding, and SAM binding affinity.
RESULTS: A133P significantly reduced SM susceptibility (elevated MIC), slowed growth, and upregulated GidB expression, whereas R96C had no phenotypic effects. CETSA showed neither mutation affected GidB-SM binding. Both mutations impaired GidB-SAM binding affinity and complex stability; A133P additionally altered protein conformation, reduced active site residue interactions, and more potently inhibited SAM binding.
CONCLUSION: The gidB A133P mutation is a novel low-level SM resistance determinant in Mtb, mediating resistance by impairing GidB-SAM binding and subsequent methyltransferase function.
METHODS: SM-resistant Mtb isolates (n = 75) were collected between June 2020-August 2021 from Shijiazhuang Fifth Hospital. gidB mutations were identified via whole-genome sequencing (WGS). Recombinant Mycobacterium smegmatis strains expressing wild-type, R96C, or A133P Mtb-gidB were constructed. MIC assay, growth curve analysis, qRT-PCR, Western blot, cellular thermal shift assay (CETSA), molecular docking, and molecular dynamics (MD) simulation were used to assess phenotypic changes, gene/protein expression, SM binding, and SAM binding affinity.
RESULTS: A133P significantly reduced SM susceptibility (elevated MIC), slowed growth, and upregulated GidB expression, whereas R96C had no phenotypic effects. CETSA showed neither mutation affected GidB-SM binding. Both mutations impaired GidB-SAM binding affinity and complex stability; A133P additionally altered protein conformation, reduced active site residue interactions, and more potently inhibited SAM binding.
CONCLUSION: The gidB A133P mutation is a novel low-level SM resistance determinant in Mtb, mediating resistance by impairing GidB-SAM binding and subsequent methyltransferase function.